Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study
Open Access
- 3 September 2026
- journal article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 10 (10)
Abstract
Context: Arginine vasopressin deficiency (AVP-D), caused by hypothalamic/pituitary damage from tumor or surgery, can be transient or chronic. Chronic AVP-D is thought to be permanent though emergent research indicates the possibility of late recovery. Little is known about clinical characteristics that predict late recovery from chronic AVP-D. Objective: Describe characteristics associated with late recovery from chronic AVP-D. Design: Multicenter, retrospective case-control study of AVP-D Recovered (n = 18) vs AVP-D Non-recovered (n = 36; matched for sex and disease duration). Main outcome measures: Clinical characteristics assessed at hypothalamic/pituitary disease diagnosis, AVP-D diagnosis, AVP-D recovery, and most recent clinical evaluation. We also present characteristics of three pediatric cases with AVP-D recovery. Results: At diagnosis of hypothalamic/pituitary disease, AVP-D Recovered, compared to AVP-D Non-recovered, were older (45 ± 19 vs 33 ± 13 years, P = .006) and more likely to have functioning pituitary tumors (33.3% vs 8.3%, P = .05). Following diagnosis of AVP-D, AVP-D Recovered received lower total daily doses of desmopressin (100 [IQR; 50, 100] vs 200 [100, 200] µg oral or equivalent, P = .01). Recovery occurred after a median of 6.3 years [1.7, 12.0] and occurred earlier in those without hypothyroidism (P = .049) or adrenal insufficiency at diagnosis of AVP-D (P = .008). Conclusion: Our study supports the notion that chronic AVP-D may not be permanent across the lifespan. Continued requirement for desmopressin, particularly in those with a history of functioning pituitary tumors, low doses of desmopressin, and without concurrent hypothyroidism or adrenal insufficiency at diagnosis, should be regularly reassessed.Keywords
Funding Information
- National Institutes of Health (K24MH120568)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (P2BSP3_195645)
- Norges Idrettshøgskole (5T32DK007529-38)
This publication has 16 references indexed in Scilit:
- Central diabetes insipidus (vasopressin deficiency) after surgery for pituitary tumours: a systematic review and meta-analysisEuropean Journal of Endocrinology, 2024
- Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiencyNature Reviews Endocrinology, 2024
- New insights on diagnosis and treatment of AVP deficiencyReviews in Endocrine and Metabolic Disorders, 2023
- Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind, placebo-controlled crossover trialThe Lancet Diabetes & Endocrinology, 2023
- Diabetes insipidusNature Reviews Disease Primers, 2019
- Recovery from diabetes insipidus and preservation of thyroid function after craniopharyngioma removal and pituitary stalk sectioningClinical Neurology and Neurosurgery, 2017
- Disorders of water metabolism following transsphenoidal pituitary surgery: A single institution’s experiencePituitary, 2006
- Chronic intermittent salt loading enhances functional recovery from polydipsia and survival of vasopressinergic cells in the hypothalamic supraoptic nucleus following transection of the hypophysial stalkBrain Research, 1996
- Diabetes InsipidusEndocrinology and Metabolism Clinics of North America, 1995
- A QUANTITATIVE EVALUATION OF HYPOTHALAMIC DEGENERATION AND ITS RELATION TO DIABETES INSIPIDUS FOLLOWING INTERRUPTION OF THE HUMAN HYPOPHYSEAL STALKBrain, 1963